Guidelines on the use of cyclosporine

- Cyclosporine has been approved for use in AD under the following conditions:

- The patient is older than age 16

- Continuous treatment is only done if appropriate monitoring is undertaken

- Intermittent doses of up to 16 weeks are recommended in most patients

- The dose should be titrated to lower renal toxicity

- If hypertension develops, the dose should be reduced or discontinued

- If an infection develops, reduce the dose of cyclosporine and manage the infection

- All patients should be educated about symptoms of infections and when to seek help

- Patients need to be monitored for nonmelanoma skin cancer

- Cyclosporine should not be used at the same time as phototherapy

- Monitor serum lipid levels